Infectious Disease Diagnostics Market: Market Size & Forecast 2026

The infectious disease diagnostics market encompasses technologies, instruments, reagents, and consumables used to detect pathogens including bacteria, viruses, fungi, and parasites. In 2025, the global market stands at approximately $27.42 billion, with multiple independent analyses projecting continued expansion to between $60 billion and $71 billion by 2033-2035. Reagents, kits, and consumables collectively account for the largest revenue share, reflecting the recurring nature of testing consumables in laboratory and clinical settings. The market is broadly divided between traditional laboratory-based testing and rapidly growing point-of-care alternatives, with molecular diagnostic platforms emerging as the dominant technology category.

• •Reagents, kits, and consumables represent over half of total market revenue due to high ongoing consumption rates
• •Molecular diagnostics platforms, led by PCR technology, hold the largest share by technology type
• •The market spans HIV, tuberculosis, respiratory infections, hepatitis, and other major infectious disease indications

The market is propelled by the rising global prevalence of infectious diseases, growing demand for rapid and accurate diagnostic results, and increasing healthcare expenditure across developed and emerging markets. The urgent need for timely diagnosis to enable appropriate treatment and infection control has accelerated adoption of molecular diagnostics and point-of-care testing in both hospital and resource-limited settings. Growing awareness of the importance of early detection, coupled with healthcare infrastructure investments, continues to expand testing volumes across clinical, public health, and consumer applications.

• •Rising prevalence of infectious diseases globally, particularly in respiratory and blood-borne infection categories
• •Increasing adoption of point-of-care testing solutions in hospitals, clinics, and low-resource settings
• •High healthcare expenditure and diagnostic infrastructure investment, especially in North America

The market is segmented across product type, technology platform, testing setting, and disease indication, with North America currently representing the largest regional market due to high healthcare spending and established diagnostic infrastructure. Asia-Pacific is emerging as a high-growth region driven by improving healthcare access, rising disease burden, and increasing adoption of advanced diagnostic technologies. Segmentation by indication includes HIV/AIDS, tuberculosis, hepatitis, respiratory infections, and other infectious diseases, with respiratory infection testing representing a particularly fast-growing category.

• •North America dominates the regional market, supported by high healthcare expenditure and advanced diagnostic infrastructure
• •Asia-Pacific is the fastest-growing region, driven by expanding healthcare access and rising infectious disease burden
• •Respiratory infection testing represents one of the largest and most rapidly expanding indication segments

What are the recent trends and outlook?

The market is experiencing a structural shift from centralized laboratory testing toward decentralized point-of-care and at-home diagnostic formats, with over-the-counter testing emerging as a significant consumer-facing category. Next-generation molecular technologies, including CRISPR-based assays and advanced sequencing platforms, are expected to drive the next wave of market expansion by enabling faster, more precise, and more accessible infectious disease detection. Through 2033-2035, the market is projected to maintain a compound annual growth rate of approximately 8-10%, with the total addressable market potentially reaching $60-71 billion as technological innovation, expanding testing indications, and growing global health investment continue to fuel demand.

• •Over-the-counter and at-home diagnostic formats are rapidly expanding, creating new consumer-facing market opportunities
• •CRISPR-based assays and advanced molecular platforms represent emerging technology segments expected to gain significant market share
• •The market is projected to reach $60-71 billion by 2033-2035, maintaining a compound annual growth rate of approximately 8-10%